Comparative evaluation of [99mTc]tilmanocept for sentinel lymph node mapping in breast cancer patients: Results of two phase 3 trials

Annals of Surgical Oncology

Volumn 20, Issue 8, 2013, Pages 2590-2599

  Wallace, Anne M ^a   Han, Linda K ^b   Povoski, Stephen P ^c   Deck, Kenneth ^d   Schneebaum, Schlomo ^e   Hall, Nathan C ^c   Hoh, Carl K ^f   Limmer, Karl K ^g   Krontiras, Helen ^h   Frazier, Thomas G ⁱ   Cox, Charles ^j   Avisar, Eli ^k   Faries, Mark ^l   King, Dennis W ^m   Christman, Lori ^m   Vera, David R ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INDIANA UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d South Orange County Medical ^*  (United States)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ BRYN MAWR HOSPITAL   (United States)

^j UNIVERSITY OF SOUTH FLORIDA   (United States)

^k UNIVERSITY OF MIAMI HOSPITAL   (United States)

^l JOHN WAYNE CANCER INSTITUTE   (United States)

^m STATKING Clinical Services   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TILMANOCEPT TC 99M;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER STAGING; CELLULITIS; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; FEMALE; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; LYMPH NODE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MASTECTOMY; NAUSEA; PHASE 3 CLINICAL TRIAL; RADIOACTIVITY; SEROMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURGERY; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; COLORING AGENTS; DEXTRANS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MANNANS; MIDDLE AGED; RADIOPHARMACEUTICALS; SENTINEL LYMPH NODE BIOPSY; TECHNETIUM TC 99M PENTETATE;

EID: 84880300454     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2887-8     Document Type: Article

References (40)

1. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-75.
2. Gipponi M, Bassetti C, Canavese G, Catturich A, Di Somma C, Vecchio C, et al. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. J Surg Oncol. 2004;85:102-11.
3. Krag DN. Current status of axillary lymph node dissection and sentinel node biopsy in breast cancer. Clin Adv Hematol Oncol. 2010;8:471-3.
4. Rodier J, Janser J. Surgical technical details improving sentinel node identification in breast cancer. Oncol Rep. 1997;4:281-3.
5. Newman LA. Lymphatic mapping and sentinel lymph node biopsy in breast cancer patients: a comprehensive review of variations in performance and technique. J Am Coll Surg. 2004;199:804-16.
6. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997;226:271-8.
7. Martin RC, 2nd, Edwards MJ, Wong SL, Tuttle TM, Carlson DJ, Brown CM, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery. 2000;128:139-44.
8. Cody HS, Fey J, Akhurst T, Fazzari M, Mazumdar M, Yeung H, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol. 2001;8:13-9.
9. 99mTc]DTPA-mannosyl-dextran. J Nucl Med. 2001;42:951-9.
10. Ezekowitz RA, Sastry K, Bailly P, Warner A. Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J Exp Med. 1990;172:1785-94.
11. Wallace AM, Hoh CK, Vera DR, Darrah D, Schulteis G. Lymphoseek: a molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol. 2003;10:531-8.
12. 99mTc]tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer. Ann Surg Oncol. 2011;18:961-9.
13. Wallace AM, Hoh CK, Ellner SJ, Darrah DD, Schulteis G, Vera DR. Lymphoseek: a molecular imaging agent for melanoma sentinel lymph node mapping. Ann Surg Oncol. 2007;14:913-21.
14. Wallace AM, Hoh CK, Darrah DD, Schulteis G, Vera DR. Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek. Nucl Med Biol. 2007;34:849-53.
15. Wallace AM, Hoh CK, Limmer KK, Darrah DD, Schulteis G, Vera DR. Sentinel lymph node accumulation of Lymphoseek and Tc-99m-sulfur colloid using a "2-day" protocol. Nucl Med Biol. 2009;36:687-92.
16. 99mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013;20:680-8.
17. Faries MB, Morton DL. Surgery and sentinel lymph node biopsy. Semin Oncol. 2007;34:498-508.
18. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881-8.
19. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426-32; discussion 432-3.
20. Rayhanabad J, Yegiyants S, Putchakayala K, Haig P, Romero L, Difronzo LA. Axillary recurrence is low in patients with breast cancer who do not undergo completion axillary lymph node dissection for micrometastases in sentinel lymph nodes. Am Surg. 2010;76:1088-91.
21. Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364:412-21.
22. Morton DL, Bostick PJ. Will the true sentinel node please stand? Ann Surg Oncol. 1999;6:12-4.
23. Meyer-Rochow GY, Martin RC, Harman CR. Sentinel node biopsy in breast cancer: validation study and comparison of blue dye alone with triple modality localization. ANZ J Surg. 2003;73:815-8.
24. Cope FO, Metz WL, Potter B, Abbruzzese B, Blue M, Shuping J, et al. The novel receptor targeted (CD206) 99mTc-labeled tilmanocept versus the currently employed 99mTc-sulfur colloid in intraoperative lymphatic mapping (ILM) on key performance metrics in breast cancer. J Clin Oncol. 2012;30(15 suppl):e21066.
25. 99mTc-labeled nanocolloid human serum albumin standard of care. Clin Exp Metastasis. 2012;29:681-6.
26. 99mTc] Tilmanocept: A synthetic receptor-targeted molecule for sentinel lymph node mapping. Radiopharmaceuticals for Sentinel Lymph Node Detection. Vienna: International Atomic Energy Agency (in press).
27. Ege GN. Internal mammary lymphoscintigraphy - the rationale, technique, interpretation and clinical application: a review based on 848 cases. Radiology. 1976;118:101-7.
28. Larson SM, Nelp WB. Radiopharmacology of a simplified technetium-99m-colloid preparation for photoscanning. J Nucl Med. 1966;7:817-26.
29. 18F labeling of a near-infrared fluorophore enables positron emission tomography and optical imaging of sentinel lymph nodes. Bioconjug Chem. 2010;21:1811-9.
30. Emerson DK, Limmer KK, Hall DJ, Han SH, Eckelman WC, Kane CJ, et al. A receptor-targeted fluorescent radiopharmaceutical for multi-reporter sentinel lymph node imaging. Radiology. 2012;265:186-93.
31. van der Poel HG, Buckle T, Brouwer OR, Olmos RAV, van Leeuwen FWB. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodel tracer. Eur Urol. 2011;60:826-33.
32. Kawaguchi Y, Ishizawa T, Masuda K, Sato S, Kaneko J, Aoki T, et al. Hepatobiliary surgery guided by a novel fluorescent imaging technique for visualizing hepatic arteries, bile ducts, and liver cancers on color images. J Am Coll Surg. 2011;212:e33-9.
33. Sirlin CB, Vera DR, Corbeil JA, Caballero MB, Buxton RB, Mattrey RF. Gadolinium-DTPA-dextran: a macromolecular MR blood pool contrast agent. Acad Radiol. 2004;11:1361-9.
34. Stroup SP, Kane CJ, Farchshchi-Heydari S, James CM, Davis CH, Wallace AM, et al. Preoperative sentinel lymph node mapping of the prostate using PET/CT fusion imaging and Ga-68-labeled tilmanocept in a dog model. Clin Exp Metastasis. 2012;29:673-80.
35. Summary of product characteristics for nanocoll, kit for radiopharmaceutical preparation. Milan: GE HEALTHCARE S.R.L.; 2009.
36. Cherry SR, Sorenson JA, Phelps ME. Physics in Nuclear Medicine. 3rd ed. Philadelphia: Saunders; 2003.
37. Krag DN, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med. 1998;339:941-6.
38. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927-33.
39. McMasters KM, Tuttle T, Carlson D, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560-6.
40. Liu LC, Lang JE, Jenkins T, Lu Y, Ewing CA, Hwang SE, et al. Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer? J Am Coll Surg. 2008;207:853-8.